cagrisema cagrilintide semaglutide phase 3 obesity Efficacy and safety of co-administered once-weekly 2·4 mg with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, 2 trial CagriSema for Obesity · Info

Additionally, the presence of publication bias suggested by Eggers test and funnel plot asymmetry indicates that smaller studies with non-significant results might be underrepresented

3 After roughly 18 months, participants lost about 10 percent of body weight, and average total testosterone increased by 18 percent, suggesting that weight reduction from GLP-1 therapy may help reverse obesity-related low testosterone

Combining compounds multiplies the number of potential side effects at play, and stacking unapproved research chemicals without medical supervision carries meaningfully more risk than using a single compound on its own

The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes

Higher doses may increase gastrointestinal side effects without improving outcomes